CASE REPORT
The patient is a 25-year-old woman with a 4-year history of a sclerotic, atrophic, and somewhat hyperpigmented 2.0 x 3.5 cm patch over her left lower eyelid, zygoma, and cheek ( Fig. 1 ). Historically the lesion had not increased in size for 2 years and was thought to be clinically inactive. The patient had no signs or symptoms of concomitant connective tissue disease, and the physical examination was normal. A biopsy of the lesion was consistent with morphea. Antinuclear antibody (ANA) and complete blood count were normal. ZCI test dose injected into her right volar forearm was nonreactive at 72 hours and at 1 month. At monthly intervals over the following 3 months, a total of 1.5 ml ZCI was implanted into the lesion up to, but not extending over, the orbital rim. The patient achieved a very good clinical correction (80%) and was entirely satisfied with the cosmetic results (Fig. 2) . This result has persisted for 1 year, and careful followup for loss of correction is anticipated. Prior to, during, and following ZCI therapy, anti-ZCI antibodies assays remained normal. The antibodies were measured in our laboratory using an ELISA assay developed and reported by Swanson et a1.* In this assay, the patient's serum has remained well within normal limits for our laboratory.
COMMENTS
For this patient, ZCI was able to correct the contour defect caused by her disease. However, the implant had no effect on the hyperpigmentation on the sclerotic texture of the lesion. The latter is in contrast to acne scarring, where ZCI often softens the existing scar (data on file, Collagen Corporation). The presence of autoimmune connective tissue disease (CTD) is an absolute contraindication to the administration of ZCI. The diagnosis of one of these diseases is made through history, serologic testing, x-rays, and other diagnostic procedures. Patients with the variant en Coup de Sabre of linear scleroderma have frequently been found to have positive ANA as well as other signs and symptoms of CTD.3,4 Our patient, by history, physical examination, and laboratory findings, did not fit this subset of scleroderma. Her disease was inactive, her physical examination was entirely normal, and her ANA was negative. For these reasons, we thought she had localized morphea only, with no predisposition to systemic disease. Serologic testing for anti-ZCI antibodies was also negative. To date, this highly specific test for anti-ZCI antibodies had been found positive in about 7% of the control population and 100% of patients who have received ZCI and exhibited a positive skin test or treatment site reaction.5 It is entirely possible that this assay can be used to screen patients a t risk to develop adverse ZCI reactions. In doing so, the list of contraindicated diseases may be modified to allow more patients to receive ZCI. In summary, we present a new indication for ZCI.
Although skin hyperpigmentation was not affected by the implants, the contour depression was elevated sufficiently to achieve satisfactory cosmesis. This correction has persisted to date, although we anticipate the need for reinjection to maintain correction in the future. Finally, anti-ZCI antibodies were negative, suggesting that the risk of an adverse response was minimal.
